Company news
Outlook Therapeutics, Inc. news in 2024
Outlook Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
December 26, 2024
Outlook Therapeutics® Streamlines Operations
December 12, 2024
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
December 3, 2024
Outlook Therapeutics® Announces Executive Leadership Transition
December 2, 2024
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
November 26, 2024
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
November 5, 2024
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment
October 16, 2024
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
September 15, 2024
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
September 12, 2024
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
September 3, 2024
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 2, 2024
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update
August 13, 2024
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 11, 2024
Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast
August 6, 2024
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
July 29, 2024
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
July 7, 2024
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
June 10, 2024
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
May 27, 2024
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
May 14, 2024
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
May 12, 2024
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
May 8, 2024
Outlook Therapeutics® to Present at the Retina World Congress 2024
May 1, 2024
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
April 28, 2024
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
April 14, 2024
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
March 21, 2024
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
March 17, 2024
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
March 11, 2024
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
February 13, 2024
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
January 30, 2024
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
January 22, 2024